Treating Advanced HL in 2019

You need to be logged in to continue. Please Log In or Register using the box at the top right of this page.

Release Date: May 31, 2019
Expiration Date: May 31, 2020

Expected time to complete this activity as designed: 15 minutes
There are no fees for participating in or receiving credit for this online activity.

Program Overview

With treatment regimens in Hodgkin lymphoma expanding, clinicians must be aware of these options, including the limitations and benefits of each approach. In this activity, Dr. Sarah Rutherford discusses CD30-directed therapy in newly diagnosed HL, relapsed/refractory HL, and the clinical trials anticipated to change clinical practice.

Target Audience

This activity is designed for multidisciplinary healthcare providers in the community setting, including hematologists, oncologists, pharmacists and other allied healthcare professionals who provide care to patients with Hodgkin lymphoma.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

  • Identify unmet clinical needs related to therapeutic strategies for newly diagnosed and relapsed/refractory HL that contributes to suboptimal outcomes
  • Outline current and emerging strategies for the treatment of advanced HL

Agenda

Treating Advanced HL in 2019 – Sarah Rutherford, MD

Instructions for Participation and Credit

This activity is eligible for credit through May 31, 2020. After this date, this activity will expire and no further credit will be awarded.

  1. Read the target audience, learning objectives, and faculty disclosures.
  2. You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
  3. Complete the educational content as designed.
  4. Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
  5. Complete the activity evaluation survey to provide feedback and information useful for future programming.
  6. Certificates for CME may be printed immediately after successfully completing the post-test and activity evaluation. Pharmacist credit will be uploaded to CPE Monitor 4 weeks following receipt of a completed, qualified form.

Faculty Biography

Sarah Rutherford, MD
Assistant Professor of Medicine
Division of Hematology/Oncology
Weill Cornell Medicine
New York, New York

Dr. Sarah Rutherford received her medical degree from the University of Virginia School of Medicine. She completed her internship and residency in internal medicine at Thomas Jefferson University Hospital in Philadelphia and her fellowship in hematology/oncology at New York-Presbyterian Hospital/Weill Cornell Medical College. She is an Assistant Professor of Medicine in the Division of Hematology/Oncology at Weill Cornell Medicine, New York City.

Dr. Rutherford has clinical expertise in lymphoma. Her research focuses on novel therapeutic strategies in B-cell lymphomas. She has received honors from Weill Cornell Medical College and the American Society of Hematology, and support from the New York State Empire Clinical Research Investigator Program, the Lymphoma Research Foundation, and the National Institutes of Health Clinical Loan Repayment Program. She has experience in caring for patients with a variety of lymphomas and hematologic disorders including Hodgkin lymphoma, chronic lymphocytic leukemia, diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, and marginal zone lymphoma.

Accreditation

MediCom CME CREDIT
Accreditation Statement: MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation Statement: MediCom Worldwide, Inc. designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ACPE CPE CREDIT
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 0.25 contact hours of Continuing Education Credit. Universal Activity Number: 827-0000-19-014-H01-P. Knowledge-based CPE activity.

In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when claiming credit for a CPE program.

Disclosures

As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.

Faculty Disclosure

Dr. Sarah Rutherford has received honoraria as a consultant from AstraZeneca, Celgene Corporation, Heron Therapeutics, Inc., Juno Therapeutics, Karyopharm Therapeutics, and Seattle Genetics, Inc.

Planning Committee Disclosures

The individuals listed below from MediCom Worldwide, Inc. reported the following for this activity: Andrea Mathis, Project Manager, Andrew Bowser, Medical Writer, Joan Meyer, RN, MHA, Executive Director, and Bill Stoff, Director of Operations, have no relevant financial relationships.

Peer Reviewer Disclosure

In accordance with MediCom Worldwide, Inc. policy, all content is reviewed by external independent peer reviewers for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.

If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at [email protected].

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Bristol-Myers Squibb, Merck and Co., Inc., and Seattle Genetics, Inc.

©2019 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242.
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.

You need to be logged in to continue. Please Log In or Register using the box at the top right of this page.